Recro Pharma, Inc. 4/A
4/A · Recro Pharma, Inc. · Filed Mar 20, 2017
Insider Transaction Report
Form 4/AAmended
SCP Vitalife Partners II LP
10% Owner
Transactions
- Sale
Common Stock
2017-03-16$7.93/sh−9,488$75,200→ 2,247,862 total - Sale
Common Stock
2017-03-14$8.04/sh−16,328$131,271→ 2,276,511 total - Sale
Common Stock
2017-03-15$8.01/sh−19,161$153,522→ 2,257,350 total
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2016.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.73 to $8.26, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.91 to $8.05, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.84 to $8.02, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4.
- [F5]This amendment corrects a previous clerical error to the "Amount of Securities Beneficially Owned Following Reported Transaction" contained in the Form 4 filed on March 16, 2017.